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Introduction: Early detection of lung cancer in high-risk individuals 
reduces mortality. Low-dose spiral computed tomography (LDCT) 
is the current standard but suffers from an exceedingly high false- 
positive rate (>96%) leading to unnecessary and potentially danger-
ous procedures. We, therefore, set out to develop a simple, noninva-
sive, and quantitative assay to detect lung cancer.
Methods: This proof-of-concept study evaluated the sensitivity/
specificity of the CyPath Early Lung Cancer Detection Assay to 
correctly classify LDCT-confirmed cohorts of high-risk control 
(n = 102) and cancer (n = 26) subjects. Fluorescence intensity 
parameters of red fluorescent cells (RFCs) from tetra (4-carboxyphe-
nyl) porphyrin (TCPP)-labeled lung sputum samples and subjects’ 
baseline characteristics were assessed for their predictive power by 
multivariable logistic regression. A receiver operating characteristic 
curve was constructed to evaluate the sensitivity/specificity of the 
CyPath assay.
Results: RFCs were detectable in cancer subjects more often than in 
high-risk ones (p = 0.015), and their characteristics differed between 
cohorts. Two independent predictors of cancer were the mean of 
RFC average fluorescence intensity/area per subject (p < 0.001) and 
years smoked (p = 0.003). The CyPath-based classifier had an overall 
accuracy of 81% in the test population; false-positive rate of 40% and 
negative predictive value of 83%.
Conclusions: The tetra (4-carboxyphenyl) porphyrin -based CyPath 
assay correctly classified study participants into cancer or high-risk 
cohorts with considerable accuracy. Optimizing sputum collection, 
sample reading, and refining the classifier should improve sensitivity 
and specificity. The CyPath assay thus has the potential to comple-
ment LDCT screening or serve as a stand-alone approach for early 
lung cancer detection.
Key Words: Sputum cytology, Porphyrin, Early detection, Lung 
cancer.
(J Thorac Oncol. 2015;10: 1311–1318)
Individuals diagnosed with late-stage lung cancer have a 5-year overall survival rate of less than 17%.1 Applying an actuarial 
model to the Surveillance, Epidemiology and End Results data, 
Goldberg et al.2 estimated that early detection of lung cancer 
had the potential to save more than 70,000 lives per year.
The National Lung Screening Trial demonstrated that 
low-dose spiral computed tomography (LDCT) improved 
lung cancer outcome relative to conventional radiography.3,4 
LDCT is the standard procedure for early lung cancer detec-
tion5 but suffers from a greater than 96% false-positive rate.3,4 
This means that for every three cancer patients correctly iden-
tified, 97 people are incorrectly scored as having lung cancer. 
Many of these people will undergo unnecessary follow-up 
procedures that carry their own morbidity and mortality. Thus, 
there is a dire need for approaches to complement or improve 
upon LDCT for early lung cancer detection.
An ideal early-screening method should be quantita-
tive, noninvasive, highly sensitive and specific, and inexpen-
sive enough to screen large at-risk populations. Obtaining and 
staining exfoliated material from sputum is relatively easy and 
inexpensive. Evidence also suggests that lung cancer detec-
tion across all stages, histological types, tumor sizes, and loca-
tions in sputum samples is possible6; however, microscopic 
observation of sputum samples without enhancement tech-
niques is labor-intensive and yielding average sensitivities 
below 40%.6 A recent multiparameter cytometric analysis of 
Feulgen-thionin–stained sputum reported a sensitivity of 78% 
at a specificity level of 50%.7 Despite these advances, there is 
still a need for better screening methods to reduce morbidity 
and mortality.
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Lipophilic and amphiphilic porphyrins have been known 
since the late 1940s to exhibit high affinity for neoplastic tis-
sue.8 Cancer cell membranes have altered lipid membrane 
compositions and metabolism compared with noncancerous 
cells.9–14 For example, most cancer cells show an increased 
uptake of low-density lipoprotein. Low-density lipoprotein’s 
capability to bind porphyrin molecules13,15,16 may explain 
in part the selective uptake of most porphyrins by cancer 
cells.13 Certain porphyrin compounds produce a characteris-
tic fluorescence that can be used for cancer detection.17,18 The 
compound tetra (4-carboxyphenyl) porphyrin (TCPP) is par-
ticularly well suited for lung cancer detection because it con-
tains carboxyl groups that become electrostatically neutral in 
the slightly acidic sputum-labeling environment, significantly 
improving its uptake into lipophilic cell membranes.13,19,20 We 
have exploited TCPP’s preferential binding and distinct fluo-
rescent signature to develop an early lung cancer detection 
assay (CyPath). We describe herein the results of a proof-of-
concept study conducted to determine the clinical sensitivity 
and specificity of this assay.
MATERIALS AND METHODS
Clinical Trial
Two minimal risk studies were registered with Clinical 
trials.gov (http://clinicaltrials.gov/ct2/show/NCT00894127 and 
http://clinicaltrials.gov/ct2/show/NCT02388074), reviewed 
and approved by the Quorum Institutional Review Board 
(Seattle, WA), and conducted according to ethical principles 
of the Declaration of Helsinki (v 1996) and Good Clinical 
Practice guidelines.
Subjects
The goal of the proof-of-concept study (NCT00894127) 
is to supplement LDCT for the diagnosis of lung cancer. We 
focused on determining the discriminative power of our assay 
between two highly comparable patient groups, and excluded 
healthy volunteers. The two groups included patients with 
confirmed lung cancer and people at high risk for developing 
lung cancer, but who were determined by a radiologist based 
on one or multiple LDCT scans to be cancer-free at the time 
of study conclusion.
Subjects greater than or equal to 18 years were recruited 
from military veterans who responded to public advertise-
ments and cancer patients being seen at the investigative 
sites (Helen F. Graham Cancer Center Christiana Care Health 
System, Newark, DE and Waterbury Pulmonary Associates, 
Waterbury, CT) from December 2009 to February 2011. 
Individuals who agreed to have their medical information 
released as indicated and who signed informed consent were 
screened and—if they met eligibility criteria—enrolled in one 
of the two distinct study cohorts. The first group included indi-
viduals at high risk for developing lung cancer but presump-
tively cancer free; the second included individuals diagnosed 
with lung cancer (biopsy-proven stages I–IV primary or recur-
rent disease in the lung parenchyma).
To be eligible in the high-risk cohort, subjects had to 
be U.S. military veterans and heavy smokers (defined as ≥20 
pack years). Inclusion of veterans in the high-risk group was 
stipulated by the State of New Mexico as a condition of study 
funding. For the second group, newly diagnosed lung cancer 
patients (not necessarily veterans) were treatment naive; those 
with recurrent tumors at least 1 year post therapy. Individuals 
with other primary cancers that had not metastasized to lung 
were eligible, but those with intrapulmonary metastases were 
not, nor were those with lung cancer that had metastasized 
to sites outside of the pleural cavity. Other exclusion crite-
ria (applicable to both cohorts) were the presence of severe 
obstructive lung disease (forced expiratory volume/second 
<30% of predicted), uncontrolled asthma (defined as daily 
wheezing or hospitalization/emergency room visit within last 
year), angina with minimal exertion, dependence on supple-
mental oxygen, resting or room air oxygen saturation of 92% 
or 84%, pregnancy, or working in the mining industry.
Though not the target population for our assay, we also 
recruited a cohort of healthy participants (NCT0238807) to 
determine whether red fluorescent cells (RFCs) might usually 
occur even in the absence of disease or of high-risk factors. 
As anticipated, obtaining adequate deep lung sputum sam-
ples from this group was difficult as healthy lungs produce 
little usable material. We were nevertheless able to evaluate 
5 out of 27 participants. For all other details on this trial, see 
Supplementary material (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A859).
Study Design
All subjects participating in NCT00894127 underwent 
initial LDCT chest scans according to International Early 
Lung Cancer Action Program protocol.21 In the high-risk 
cohort, LDCT scans were conducted at the investigational 
site (Radiology Associates of Albuquerque, Albuquerque, 
NM) and helped identify subjects who were potentially 
ineligible because of suspected lung cancers (i.e., presence 
of pulmonary nodules on LDCT that did not resolve before 
study closure). For the cancer cohort, LDCT was conducted 
at the investigational sites (Helen F. Graham Cancer Center 
and Waterbury Pulmonary Associates) and served to confirm 
the subject’s lung cancer diagnosis and identify the location/
extent of their disease.
Our initial intent was to include Papanicolaou (PAP) 
staining as a base of comparison to CyPath. Early evalu-
ation, however, of the readings from the PAP-stained slides 
revealed that PAP could detect cancer cells in only 18.75% 
of the cancer cohort subjects (see Supplementary Tables A 
and B, Supplemental Digital Content 2, http://links.lww.com/
JTO/A860, which show the results of the PAP-stained sputum 
slides for each cohort). With such poor sensitivity to detect 
true positives, it was decided to eliminate the CyPath com-
parison with PAP analysis from the study. PAP staining was 
thereafter only used to confirm the presence of macrophages, 
which signaled sample adequacy.
Laboratory technicians scoring CyPath-labeled samples, 
cytotechnologists scoring PAP specimens, and the radiologists 
reading the LDCT scans were blinded to the subjects’ iden-
tity and cohort membership. CyPath, PAP, and LDCT results 
were not shared between specimen readers and radiologists. 
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Participants were not systematically informed about PAP or 
CyPath findings and no clinical recommendation or protocol-
specific follow-up was based on PAP or CyPath results; how-
ever, subjects in the high-risk cohort who displayed at least 
one nodule on the initial LDCT scan were contacted, advised 
to have follow-up LDCT scans at the Radiology Associates 
of Albuquerque investigational site in accordance with 
International Early Lung Cancer Action Program recommen-
dations21 and were followed by telephone contact for at least 
18 months. Follow-up LDCT scan results were provided to a 
radiologist who determined whether the subject’s pulmonary 
nodules had resolved or stabilized and therefore could be con-
sidered cancer free and included in the high-risk group.
Sample Collection
All subjects participating in NCT00894127 were trained 
by the investigative site respiratory therapist/nurse on the 
first sample collection, using either the Lung Flute (Medical 
Acoustics; Buffalo, NY) or Acapella (Smiths Medical, St. 
Paul, MN). Both are FDA-approved, hand-held devices that 
help to thin and mobilize mucus secretions from within the 
lung. Medications that could impede sputum production were 
stopped within 2 days before sample collection. Subjects were 
instructed to use the device in accordance with manufacturer’s 
instructions and expel the sputum sample into a numbered 
sterile collection cup. Individuals repeated this procedure at 
home to collect the second and third sputum samples. Those 
who could not produce a sample in the morning were asked 
to repeat the attempt one to two times that day or the next day. 
Subjects were instructed to store their specimen cup in a cool 
dark place or in a refrigerator and to return it to the site of 
initial collection within 3 days after collection was complete.
Of note, the majority of the sputum samples in this trial 
were collected with the Lung Flute. The Acapella was intro-
duced as an alternative to the Lung Flute when 14 high-risk 
subjects were unable to produce satisfactory samples. When 
asked to repeat collection using the Acapella, 12 out of this 
same group of 14 subjects produced a sample of good qual-
ity (Supplementary Table 1, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A861, which shows the results of 
the Lung Flute versus Acapella comparison).
Sample Processing
The specimen cup was delivered to the laboratory where 
each subject’s specimen was transferred on the day of deliv-
ery to vials containing a buffered CytoLyt fixative solution 
(Hologic, Bedford, MA), pH 7 and stored at 2 to 8°C until 
processing. Specimens were centrifuged, the supernatant 
decanted, and the pellet resuspended in PreserveCyt solution 
(Hologic), pH 5.5. Thirteen slides per specimen, each with 
approximately 50,000 cells, were prepared with a ThinPrep 
machine (Hologic). Of these, 12 slides were immersed in 
the CyPath labeling solution and processed further for scor-
ing (see below). One slide was shipped to Denver Veterans 
Administration Medical Center for PAP staining to evaluate 
for the presence of bronchial macrophages. Any unused pel-
let specimen was stored frozen at −20°C and discarded after 
study close.
PAP Staining
One slide from each subject was prepared on the 
ThinPrep platform (Hologic), and PAP staining was per-
formed. This slide was evaluated by a cytopathologist. 
Samples were deemed adequate if they showed minimal 
mucous contamination, consisted of a monolayer of cells, and 
contained at least five free alveolar macrophages (FAMs) as 
a confirmation that the sample came indeed from within the 
lung; FAMs play an important defense role deep inside the 
lung, i.e., in the distal alveolar ducts and alveoli.22 Individuals 
with inadequate samples were asked once to repeat the sputum 
collection procedure.
Labeling and Scoring
Labeling solution for the CyPath assay was prepared by 
dissolving TCPP (Frontier Scientific, Inc., Logan, UT) in iso-
propyl alcohol, to which deionized water, sodium bicarbon-
ate (for pH adjustment), and 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer solution, pH 6.1, were added. For CyPath 
processing, specimen slides were first immersed in MES 
buffer, blotted dry, and then immersed in CyPath-labeling 
solution, blotted and rinsed again in MES before air drying 
and fixing with Cytoseal (Richard-Allan Scientific Cytology 
Reagents, Kalamazoo, MI).
Two laboratory technicians viewed the CyPath-labeled 
slides using an Olympus BX40 fluorescent microscope 
(Olympus Scientific Solutions Americas Corp., Waltham, 
MA) with a mercury vapor lamp filtered for 477.5 (±17.5) nm 
as the excitation source and an Olympus U-MWIB3 fluores-
cent filter cube. A standardized viewing protocol was followed. 
First, slides were screened for the presence of TCPP-labeled 
RFCs under 10 times magnification. RFCs were defined as 
circular/oval in shape with a defined perimeter and rounded 
edges, diameter greater than or equal to 8 μM, and fluorescing 
brightly red. Second, each RFC was evaluated under 20 times 
magnification for their characteristic spectral signature using 
CRi Nuance image analysis software (Cambridge Research 
and Instrumentation, Woburn, MA).
To estimate the background fluorescence intensity (FI) 
and size distributions of all cells (not just RFCs), one slide 
per subject was selected at random, and all cells within the 
field of view were measured as above at a series of predeter-
mined coordinates until data for 100 cells had been captured. 
In addition to this background control, we also measured FI 
in sputum samples obtained from healthy volunteers (see 
Supplementary material, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A861, which describes the results 
of the clinical trial for sputum analyses of healthy volunteers) 
showing that healthy sputum does not contain RFCs and that 
the background is very low compared with that of high-risk 
and cancer patients.
Statistical Analysis
In addition to RFC numbers per subject, quantitative 
measurements of 12 imaging parameters were collected on 
each RFC (collectively referred to hereafter as CyPath param-
eters). Fisher’s exact test was used to compare the number of 
samples in each cohort that had at least one RFC. To construct 
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the classifier, a forward stepwise multivariable logistic regres-
sion analysis was performed using the Statistical Package for 
the Social Sciences software from IBM (Armonk, NY) to 
determine if any patient baseline characteristic(s) or CyPath 
parameter(s) were significant independent predictors of a sub-
ject’s cohort membership. The regression coefficients of vari-
ables had to be significantly different from 0 (p <0.05 initially 
and ≤0.10 after adjustment for other variables at any stage) to 
be retained in the model. The final fitted logistic model was 
used to estimate the probability of having cancer for each sub-
ject. Different cutoff values were used to convert the estimated 
probability into a binary cancer/no cancer classification. For 
each cutoff value, the associated sensitivity and specificity for 
the prediction, compared with the known cancer status of each 
subject, was determined and the results are plotted as a receiver 
operating characteristic (ROC) curve. A nonparametric rank 
test was used to compare the area under the ROC (AU-ROC) 
curve to an area of 0.5 achievable by chance alone.
RESULTS
Study Subjects and Baseline Characteristics
For the high-risk cohort (Fig. 1), a total of 366 veter-
ans were informed about the study and underwent a screening 
interview. Of these, 233 were either ineligible, did not return 
after expressing initial interest, or refused to sign consent, and 
133 were enrolled. Of these, 20 were unable to provide an 
adequate sputum sample. The initial LDCT scan was normal 
in 69 participants, but 44 had detectable pulmonary nodules. 
Of the 44 subjects with nodules, 33 either resolved or did not 
progress during follow-up. The remaining 11 subjects were 
excluded from the study as they could either not be contacted 
or the investigators could not confirm that their nodules had 
resolved by study closure. The high-risk cohort thus com-
prised 102 subjects (69 nodule-free subjects plus 33 with 
resolved or stable pulmonary nodules).
For the cancer cohort, a total of 85 lung cancer patients were 
informed about the study; 37 were either ineligible or refused 
to consent. Forty-eight agreed to participate and were enrolled 
(Fig. 1). The initial LDCT scan revealed that five of these cancer 
patients had lung cancer that had spread outside the pleural cav-
ity and were therefore excluded per protocol. Seventeen subjects 
were unable to produce an adequate sputum sample. The remain-
ing 26 participants comprised the final cancer cohort.
Table 1 shows baseline characteristics of the two 
cohorts. A higher proportion of male than female sub-
jects were enrolled in each cohort, more so in the high-risk 
cohort, reflective of the gender composition among veterans. 
Consequently, gender was excluded from consideration as a 
predictive model parameter. The cancer cohort had a longer 
smoking history (p = 0.010).
Predictive Parameters
Cells identified as RFCs were distinct from surround-
ing background cells (Fig. 2) visually (A) and by their photon 
High-risk Cohort
n = 366 in initial 
screen
Lung Cancer Cohort
n = 85 in initial 
screen
133 eligible and signed 
consent
129 evaluated by 
pathologist
113 with adequate 
sputum samples
69 with normal 
LDCT
102 final
48 eligible and signed 
consent
36 evaluated by 
pathologist
26 with adequate 
sputum samples
26 final
151 ineligible and
82 refused or no show
26 ineligible and
11 refused
3 did not return a 
sample and 
1 unable to produce 
sputum
5 with cancer outside 
lung cavity on LDCT,  
4 unable to produce 
sputum, 2 did not 
return a sample 
and 1 sample was lost 
in transit 
9 with inadequate 
sputum samples and 
1 unreadable
44 with pulmonary 
nodules on LDCT
11 unresolved or not 
confirmed stable
33 resolved or 
confirmed as stable
16 with inadequate 
sputum samples
FIGURE 1.  Subject enrollment and participation.
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emission profiles (B). No RFCs were detected in slides from 
healthy participants. Overall, a significantly higher proportion 
of subjects with cancer (20 of 26, 76.9%) had greater than or 
equal to one RFC than the high-risk group (51 of 102, 50%; 
p = 0.015). Nevertheless, RFCs could be detected in both 
groups, so that the presence of RFCs in and of itself was not 
a sufficient discriminator of class membership. We, therefore, 
undertook to identify key characteristics of the subjects and of 
the RFCs from each of the two test cohort.
The CyPath parameters (Table 2) included several direct 
FI values, cell size measurements, measures of FI scatter (SD), 
and derived ratios of FI/area. Between cohorts, differences 
were statistically significant for two CyPath parameters and 
one approached significance. These were the mean of RFC per 
subject of average FI (FI
avg_mean
, p = 0.017), mean per subject 
of maximum FI (FI
max_mean
, p = 0.032), and the mean ratio of 
FI
avg
/area ([FI
avg
/area]
mean
, p = 0.051).
All CyPath parameters listed in Table 2 plus subject age, 
pack years of smoking, and number of years smoked were 
evaluated as candidate predictors. The aim of this approach 
was to identify features whose inclusion in the predictive 
model significantly improved the model’s goodness-of-fit 
to the data. Of the demographic and baseline characteris-
tics assessed, the number of years smoked was a significant 
predictor of cohort membership (p = 0.003). Of the CyPath 
parameters, the (FI
avg
/area)
mean
 was a significant predictor 
TABLE 1.  Demographics and Baseline Characteristics of Study Participants
High Risk Cohort, N = 102 Lung Cancer Cohort,a N = 26 P Value
Males, n (%) 95 (93.1) 16 (61.5) <0.001b
Females, n (%) 7 (6.9) 10 (38.5)
Age, mean years ± SD (range) 57.2 ± 11.6 (28–90) 61.5 ± 9.3 (42–76) 0.081c
Smoking history
  Mean pack years ± SD (range) 49.4 ± 26.1 (18–51) 52.2 ± 38.2 (0–185) 0.667c
  Mean years smoked ± SD (range) 33.0 ± 10.4 (12–60) 39.5 ± 14.7 (0–60) 0.010c
  Mean years since stopped (range) 6.0 ± 10.2 (0–55) 3.6 ± 7.0 (0–29)d 0.186c
aThe high-risk cohort excluded nonsmokers and the cancer cohort did not. Inclusion into the cancer cohort required that a participant had been diagnosed with lung cancer and that 
treatment had not started. Two of the cancer cohort subjects had never smoked.
bFisher’s exact test (two-sided).
cStudent’s t test (two-sided).
dn = 24 because two cancer cases never smoked.
FIGURE 2.  Characteristics of CyPath-stained cells. A, The intense red color of red fluorescent cells (RFCs) indicates uptake of 
tetra (4-carboxyphenyl) porphyrin (TCPP) and demonstrates a characteristic fluorescence when viewed after exposure to blue 
light (of a mercury vapor light source) through an Olympus U-MWIB3 filter. This is in contrast to surrounding background cells 
(A, background) which do not take up TCPP and appear dull when viewed under these conditions. B, Spectral emission profiles 
for the cells identified by arrowheads in A. C, Average fluorescence intensity (FI) versus log10 area of cells chosen at random 
(green, grey, blue) and of RFCs from high-risk (orange) and cancer (black) cohorts. The distinction between large and small was 
based on the k-means (k = 2) partitioning of the log10 area of background cells.
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(p < 0.001). The other factors assessed were not significant 
and therefore not included in the model. Figure 2C shows 
the distribution of average FI versus log
10
 area of RFCs from 
the two test groups and of randomly selected cells from their 
slides and from healthy participant slides as a background 
control. RFCs from both cohorts were of an intermediate size. 
There was a tendency for the RFCs from the high-risk cohort 
to be dimmer as a group, consistent with (FI
avg
/area)
mean
 as a 
predictor of group membership.
After adjusting for (FI
avg
/area)
mean
 and pack years, all remain-
ing variables had p values greater than 0.10 and were, therefore, 
excluded from the final model. Along with the other model met-
rics, Table 3 shows that the odds ratio (OR) for the CyPath param-
eter, (FI
avg
/area)
mean
, was 8.707, whereas the OR of years smoked 
was 1.068, indicating a greater impact of the CyPath variable 
on predicting the likelihood of a subject having cancer.
Sensitivity and Specificity
Absence of RFCs in the CyPath-stained slides of 6 out 
of 26 subjects with cancer suggests a potential upper bound 
on sensitivity for cancer detection of 77.9% when 12 slides 
(or ~600,000 cells) are scanned; resulting in a corresponding 
specificity of 65.7%. The predictive capabilities of the CyPath 
assay classifier for cases with RFCs detected were estimated 
from the final fitted model with (FI
avg
/area)
mean
 and number of 
years smoked as its variables. The ROC curve in Figure 3 shows 
the response in true-positive (sensitivity) and false-positive 
(1-specificity) rates as we varied the fitted model probability 
estimate cutoff. The AU-ROC curve was 0.77 ± 0.51 (standard 
error under the nonparametric assumption; 95% confidence 
interval: 0.67–0.87), significantly greater than the AU-ROC 
of 0.50 theoretically achievable by random assignment of sub-
jects to cancer/control groups (p < 0.001), indicating that the 
CyPath assay can distinguish between true positives and true 
negatives significantly better than chance alone.
The standard cutoff probability of 0.5 was used to esti-
mate overall predictive accuracy. The fitted model in this case 
correctly classified 98 out of 102 (96.1%) high-risk partici-
pants and 6 out of 26 (23.1%) cancer subjects, for an overall 
accuracy of 81.3%, a false discovery rate of 40%, and negative 
predictive value of 83%.
DISCUSSION
Screening for lung cancer using sputum is appeal-
ing because it is noninvasive, simple, requires no exposure 
to radiation, and is relatively inexpensive, although having 
the potential to detect very early disease.7,23 Overall, 88% of 
the high-risk group was able to provide a sample with FAMs 
TABLE 2.  CyPath Parameter Values for Subjects with Greater than or Equal to One Red Fluorescent Cell (RFC)
High-Risk Cohort (n = 51) Cancer Cohort (n = 20) P Value
No. of RFCs 2.6 ± 3.0 (1–19) 2.2 ± 2.0 (1–9) 0.537
Mean RFC FI
avg
 (FI
avg_mean
) 346.5 ± 154.9 (106–898) 457.3 ± 209.1 (104–889) 0.017
Mean RFC FI
max
 (FI
max_mean
) 410.5 ± 200.3 (106–1019) 533.4 ± 266.1 (104–985) 0.072
Maximum FI
avg
 (FI
avg_max
) 685.7 ± 306.9 (298–1985) 871.9 ± 362.4 (264–1714) 0.032
Maximum FI
max
 (FI
max_max
) 815.3 ± 423.5 (298–2803) 988.2 ± 422.0 (264–1787) 0.126
Mean cell diameter (pixel diametersa) 33.1 ± 10.5 (18–65) 33.0 ± 12.6 (18–61) 0.954
Maximum cell diameter (pixel diameters) 38.1 ± 14.7 (18–82) 37.3 ± 14.9 (18–63) 0.838
Mean cell area (pixelsb) 1150.3 ± 745.7 (304–3730) 1129.9 ± 899.6 (258–3336) 0.922
Maximum cell area (pixels) 1558.2 ± 1266.5 (304–6109) 1317.0 ± 952.5 (258–3368) 0.444
Mean FI
SD
 (FI
SD_mean
) 130.1 ± 73.4 (45–353) 165.9 ± 81.7 (31–353) 0.078
Mean maximum FI
SD
 (FI
SD_max
) 160.2 ± 96.0 (45–487) 191.4 ± 90.1 (31–355) 0.214
Mean ratio of FI
avg
/area ([FI
avg
/area]
mean
) 0.478 ± 0.311 (0.05–1.40) 0.751 ± 0.562 (0.03–1.97) 0.051
Mean ratio of FI
max
/area ([FI
max
/area]
mean
) 0.661 ± 0.530 (0.05–2.87) 0.910 ± 0.690 (0.03–2.07) 0.157
FI measurements are the number of photons emitted per pixel per half-second.
Parameters significantly (or borderline) different between groups are shaded grey.
Mean values are shown ± standard deviation with ranges shown beneath in parentheses.
aPixel diameter = 0.492 μm.
bPixel = 0.242 μm2.
FI
avg
, average fluorescence intensity; FI
max
, maximum fluorescence intensity; FI
SD
, standard deviation fluorescence intensity.
TABLE 3.  Multivariable Logistic Regression Model Predictors of Cohort Membership
B SE Wald df P Value
Odds Ratio 
(OR)
95% CI for OR
Lower Upper
Mean (FI
avg
/area) 2.164 0.574 14.220 1 <0.001 8.707 2.827 26.814
No. of years smoked 0.066 0.022 8.778 1 0.003 1.068 1.022 1.115
Constant −4.576 0.979 21.824 1 <0.001 0.010
B, intercept; SE, standard error around B; Wald, P value of the Wald chi-square test; df, degree of freedom; CI, confidence interval.
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associated with deep lung expectoration. Use of the Acapella 
device, in particular, seemed to result in a better sputum pro-
duction than with the Lung Flute. In both cases, collection 
was accomplished fairly quickly with little difficulty and no 
adverse consequences for the subject.
The fluorescence emission characteristics of CyPath-
labeled cells were quantifiable and distinguishable from back-
ground, making the identification of RFCs straightforward. 
Within the positive control cancer cohort, 23% of participants 
had no RFCs detected in the 12 slides (~600,000 cells) evalu-
ated. If RFCs are distributed randomly according to a Poisson 
distribution in the cancer samples, our results suggest a fre-
quency of roughly 1.5 RFC per 12 slides (20 of 26 with at 
least one RFC). We would, therefore, expect that doubling the 
number of cells examined, for example, could increase RFC 
detection to 95%.
Age and pack years of smoking are clearly risk factors 
for developing lung cancer, but they are less accurate than risk 
prediction models in identifying people who will develop lung 
cancer and die from the disease.24 The aim of this proof-of-
concept study was to determine whether CyPath labeling could 
be usefully incorporated into a predictive model. We found 
that the number of years smoked was a predictor of being in 
the cancer cohort though the associated OR was a modest 1.1. 
Importantly, one of the RFC parameters, mean FI
avg
/Area, also 
had a positive predictive value (PPV) with an OR of 8.7. When 
combined in a classifier, these two variables allowed us to cor-
rectly assign subjects to the cancer or high-risk cohorts with 
an accuracy of 81% and PPV of 60% on this data set. Our 
focus in this study was to determine the discriminatory power 
of our assay between two highly similar patient groups. Our 
results indicate that further optimization of predictive model 
parameters and of sputum harvesting and processing would 
likely improve our classification accuracy for these populations.
We have deliberately excluded patients with noncancer-
ous pulmonary diseases from consideration to maintain the 
focus of this analyses, but our findings now make a compelling 
case for exploring further applications of CyPath labeling to 
these diseases. Others have reported that porphyrins are pref-
erentially taken up by cancer cells,8 and this study shows that 
features of RFCs are positive discriminators for the presence 
of cancer. Moreover, we observed that the (FI
avg
/area)
mean
 of 
RFCs in cancer patients diagnosed with adenocarcinoma was 
higher than that in patients with squamous carcinoma (data 
not shown). Together, these observations suggest that RFCs 
are related to lung cancer. The true nature of RFCs remains 
unclear because they were also found in sputum samples from 
the high-risk group, who during the period of the trial were not 
diagnosed with cancer. The follow-up of patients in our study 
was relatively short. It is thus possible that in some of these 
individuals the RFCs present early signs of cancer, before it 
became obvious by LDCT. Importantly, our data show that 
the (FI
avg
/area)
mean
 of the RFCs detected in the sputum of the 
high-risk cohort is lower than in the cancer cohort. This may 
present a true biological difference, e.g., a different cell type, 
and follow-up studies will address this issue. Moreover, future 
studies will also be aimed at identifying a cut-off value of the 
(FI
avg
/area)
mean
 above which a cancer diagnosis is more likely, 
thus further improving our classification accuracy.
In conclusion, the CyPath assay has the potential to 
satisfy the requirements of an early lung cancer screening 
methodology: the starting material is readily acquired, the 
staining protocol is straightforward and scalable, evaluation 
of TCPP staining is both quantitative and amenable to high-
throughput processing, and the classifier based on smoking 
history and TCPP fluorescence characteristics is already rea-
sonably accurate and predictive. Our proof-of-concept results 
are particularly encouraging when compared with the corre-
sponding values for LDCT of 74% accuracy and 3.8% PPV.4 
Further development of this promising technology, followed 
by validation trials in lung cancer patients and control groups, 
therefore, seems both warranted and of potential future clini-
cal value.
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